Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The latest announcement is out from LakeShore Biopharma ( (LSB) ).
LakeShore Biopharma reported significant financial improvements for the first half of fiscal year 2025, achieving a total revenue of RMB 371.9 million, a 36.2% increase year-over-year, and recording a net income of RMB 20.6 million, the first since 2013. This financial turnaround is attributed to strategic initiatives in cost reduction and operational efficiency, despite challenging market conditions in China. Furthermore, the company received approval for a phase III clinical trial for its YSJA rabies vaccine, aiming to enhance its market position and clinical competitiveness.
More about LakeShore Biopharma
LakeShore Biopharma, formerly YS Biopharma, is a global biopharmaceutical company focused on developing and delivering vaccines and therapeutic biologics for infectious diseases and cancer. The company operates in China, the United States, Singapore, and the Philippines, utilizing its proprietary PIKA® immunomodulating technology platform to target diseases such as Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles.
YTD Price Performance: -52.00%
Average Trading Volume: 45,619
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $46.81M
For a thorough assessment of LSB stock, go to TipRanks’ Stock Analysis page.
